GEN Exclusives

More »

GEN News Highlights

More »
Nov 16, 2007

Argos Licenses T-Cell Technology to Therakos

  • Argos Therapeutics signed an exclusive licensing agreement with Therakos, a Johnson & Johnson company, for the research and development of new treatments based on Argos’ regulatory T-cell technology.

    Argos is actively developing immunotherapies or indications such as cancer, infectious diseases, autoimmune disorders,  and transplantation using its Arcelis technology, which trains the immune system to recognize and attack the disease.

    “The licensing agreement with Therakos will enable accelerated development of an asset outside our primary focus, while providing Argos with nondilutive financial resources,” said John Bonfiglio, Ph.D., president and CEO at Argos Therapeutics. “This transaction further demonstrates our ability to leverage Argos´ leading immunotherapy science both through our own programs as well as through collaborations with select corporate partners."



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

Be sure to take the GEN Poll

Using CRISPRs to Tame GMOs

With more climate-induced droughts and insect infestations on the horizon do you think technologies like CRISPR will change a lot of people’s minds about GMOs, including genetically engineered foods?

More »